Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155342 | 1.00 | HPGD (0.57) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19444563 | 0.99 | HPGD (0.56) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29276715 | 0.94 | HPGD (0.55) | HPGDALDH1A1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL20648152 | 0.94 | HPGD (0.52) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15298801 | 0.94 | HPGD (0.52) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14341782 | 0.94 | HPGD (0.52) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10310074 | 0.94 | HPGD (0.61) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL725097 | 0.94 | HPGD (0.55) | HPGDALDH1A1SMN1; SMN2HDAC3HDAC4 | |
| SCHEMBL16298865 | 0.93 | HPGD (0.54) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29276718 | 0.93 | HPGD (0.57) | HPGDALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025107412-A1 | USE OF SHRIMP HEMOCYANIN AS HAPTEN CARRIER PROTEIN | 上海雅酶生物医药科技有限公司 | 2025-05-30 | — | — | WO | claimed |
| CN-120040581-A | Application of shrimp hemocyanin as hapten carrier protein | 上海雅酶生物医药科技有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025010117-A1 | INFLUENZA B HEADLESS HA UNIVERSAL VACCINES | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-01-09 | — | — | WO | claimed |
| US-20240052005-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2024-02-15 | — | — | US | claimed |
| EP-4263582-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | Anastasis Biotec Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| WO-2022129926-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2022-06-23 | — | — | WO | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102333-A1 | METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4739804-A1 | METHODS AND COMPOSITIONS FOR CHARACTERIZING VIRAL PARTICLES IN A BIOLOGICAL SAMPLE | NanoMosaic Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735051-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612456-B2 | CD19 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220062434-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2022040822-A1 | METHOD FOR RAPIDLY OBTAINING ALBUMIN NANOPARTICLES LOADED WITH MAGNETIC NANOPARTICLES | UNIVERSIDAD TÉCNICA FEDERICO SANTA MARÍA (CL) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022047085-A1 | SENSORS FOR UNBIASED PROTEOMIC STUDIES, METHOD OF MANUFACTURE AND USE THEREOF | NanoMosaic INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022047176-A2 | SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3953385-A1 | CD19 ANTIBODIES AND METHODS OF USING THE SAME | Memorial Sloan Kettering Cancer Center (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022032003-A2 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | ABPRO CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612456-B2 | CD19 antibodies and methods of using the same | CD74, CD4, CD2 | HPGD 4818/4885ALDH1A1 4081/4885SMN1; SMN2 3178/4885 |
| US-20220062434-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MTPN, MYOF, TNNC1 | HPGD 2847/4885ALDH1A1 4206/4885SMN1; SMN2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.